Showing 3004 results
-
Story /For a quarter of a century, Novartis and The Max Foundation have worked together to help people living with cancer in low- and middle-income countries access the care they need.
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Basel, September 4, 2026 – Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR REMODEL-1/-2 trials met their primary endpoint, significantly reducing annualized relapse rate (ARR) vs teriflunomide in people living with…
-
Story /Novartis R&D is harnessing digital technologies to make smart decisions faster, aiming to reduce the time it takes to bring new options to patients